Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Obinutuzumab + Chlorambucil	216
Overall Study	STARTED	Obinutuzumab + Venetoclax	216
Overall Study	STARTED	Safety Run-in Obinutuzumab + Venetoclax	13
Overall Study	Treated	Obinutuzumab + Chlorambucil	214
Overall Study	Treated	Obinutuzumab + Venetoclax	212
Overall Study	Treated	Safety Run-in Obinutuzumab + Venetoclax	13
Overall Study	COMPLETED	Obinutuzumab + Chlorambucil	0
Overall Study	COMPLETED	Obinutuzumab + Venetoclax	0
Overall Study	COMPLETED	Safety Run-in Obinutuzumab + Venetoclax	0
Overall Study	NOT COMPLETED	Obinutuzumab + Chlorambucil	216
Overall Study	NOT COMPLETED	Obinutuzumab + Venetoclax	216
Overall Study	NOT COMPLETED	Safety Run-in Obinutuzumab + Venetoclax	13

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02242942/flow